GO
| HSI1 | 24,788.14 | 0.00 | -- |
| HSCEI1 | 8,374.30 | 0.00 | -- |
| Back Zoom + Zoom - Block Traded | |
|
2026-03-31 04:47:42 3SBio (01530.HK) announced its 2025 annual results, reporting revenue of RMB17.696 billion, up 94.3% year-on-year, primarily due to licensing revenue from a breakthrough PD-1/VEGF bispecific antibody 707 licensing deal with Pfizer. The company recorded a net profit of RMB8.482 billion, a growth of 305.8%, with an EPS of RMB3.51. The final dividend is maintained at HKD0.25. During the year, gross profit was RMB16.347 billion, up 108.8%, with the gross profit margin increasing from 86% to 92.4%. (de/d)~ AASTOCKS Financial News Website: www.aastocks.com | |